drugset / Trial / NCT00104377

Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen

NCT00104377 ↗

Phase 2 Completed 70 enrolled Allergy Therapeutics
RandomizedParallel-groupSingle-blindTreatment

Summary

Grass MATA (modified pollen allergen tyrosine adsorbate) has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to grass and rye pollen. Different doses of Grass MATA will be administered and immunological changes following this treatment will be assessed.

Timeline

Start
2005-03
Primary completion
—
Completion
2005-11

Outcome

Met primary endpoint

release “Grass MATA MPL Phase II dose ranging study - Primary endpoint met” allergytherapeutics.com ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Grass MATA Other / unclassified — Subcutaneous